New York, Jan 25, 2026, 07:11 ET — Market closed
- Kenvue closed Friday at $17.80, gaining 0.3%, as investors focused on the merger vote scheduled for next week
- Deal value moves with Kimberly-Clark’s share price; the implied offer is just above Kenvue’s closing price
- Proxy documents highlight shareholder lawsuits targeting merger disclosures, underscoring risks of timeline delays
Kenvue Inc shares ended Friday up just 0.05, settling at $17.80. The slight gain kept the stock closely tied to the numbers behind its upcoming deal with Kimberly-Clark.
U.S. markets were closed Sunday, so price discovery will kick off again Monday. Then on Thursday, Kenvue shareholders will meet online to vote on the deal.
The merger spread is still evident at the latest prices. Kimberly-Clark last traded near $102.23. The deal terms—$3.50 in cash plus 0.14625 Kimberly-Clark shares—value each Kenvue share at about $18.45, roughly 65 cents above Friday’s closing price, before factoring in time and deal risk.
In late Friday trading, Kenvue held steady at $17.76 in delayed quotes, showing little movement from the closing price.
Kimberly-Clark and Kenvue have positioned the deal as a move into consumer health, targeting roughly $1.9 billion in cost synergies. The transaction is slated to close in the second half of 2026, pending shareholder and regulatory approvals.
Proxy adviser Institutional Shareholder Services urged investors to support the deal, despite noting ongoing litigation tied to Kenvue’s talc products and concerns about Tylenol’s active ingredient.
Traders see this mainly as a merger-arbitrage play: pick up the target, short the acquirer, and aim to pocket the “spread” — that difference between Kenvue’s current price and the deal’s implied worth — assuming the vote passes and the deal closes.
The deal hasn’t been free of concerns from the get-go. Jay Woods, chief market strategist at Freedom Capital Markets, noted post-announcement that some investors worry Kimberly-Clark “may be buying damaged goods.” Their unease centers on unresolved litigation linked to Kenvue brands. Reuters
Kenvue’s filings reveal a steady stream of shareholder complaints and demand letters accusing the company of missing merger details. Plaintiffs want the vote postponed until more information is provided. Kenvue says it’s updating disclosures to lower the chance of any disruption.
But the spread works both ways. If Kimberly-Clark shares falter, the implied takeover price drops right away. And delays in closing could deter arbitrageurs, particularly with several court cases still hanging over the deal.
Investors face a key date on Jan. 29: Kimberly-Clark’s special meeting kicks off at 8:00 a.m. Central. Kenvue’s vote happens that same day, with the market focused on smooth approvals and any last-minute legal or disclosure surprises.
Related articles: NYSE:KVUE
